Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

Authors not listed

Novartis Pharmaceuticals · 2025

Dysbiosis Human Randomized controlled trial

Abstract

This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-11-11 MST

Cite this

APA

Anonymous. (2025). A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension. <em>Novartis Pharmaceuticals</em>. https://clinicaltrials.gov/study/NCT07094516

Vancouver

Anonymous. A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension. Novartis Pharmaceuticals. 2025.

BibTeX

@misc{anon2025ARando, title = {A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension}, author = {Anonymous}, journal = {Novartis Pharmaceuticals}, year = {2025}, }